Compare Genworth Financial Inc Common Stock (GNW) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genworth Financial Inc Common Stock vs Smith & Nephew plc — how do they compare? Genworth Financial Inc Common Stock trades at $8.82 (market cap $3.33B), while Smith & Nephew plc trades at $28.24 (market cap $11.65B). The key difference: Smith & Nephew plc is far larger — about 3.5× Genworth Financial Inc Common Stock's market cap, and Smith & Nephew plc pays a 2.85% dividend while Genworth Financial Inc Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Genworth Financial Inc Common Stock for 0 Days and Smith & Nephew plc for 121 Days on average.
| GNW | SNN | |
|---|---|---|
Market Cap | $3.33B | $11.65B |
Volume | 3,324,561 | 860,347 |
Sector | Financials | Health |
52-Week High | $10.60 | $37.17 |
52-Week Low | $7.94 | $26.42 |
Typical Hold Time | 0 Days | 121 Days |
Enterprise Value | $2.85B | $14.68B |
Dividend Yield | — | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Genworth Financial (GNW) trades at $8.89, down 1.77% today, with neutral technical signals and mixed fundamental performance. The company maintains stable revenue around $7.1-7.2B but faces margin pressure, with net income declining from $223M to $212M year-over-year. Recent Q2 2026 earnings beat expectations at $0.29 EPS, while the company expanded its share repurchase program by $500M in September 2026.
GNW presents value characteristics with low P/B (0.38) and P/S (0.49) ratios, but weak profitability metrics (ROE 2.42%) and analyst caution (70.59% hold rating) suggest limited near-term catalysts. Key risks include legacy insurance liabilities and competitive pressures, while the upcoming Q3 earnings on November 4 could provide directional clarity.
SNN trades at $27.86, near a 52-week low, with a mixed technical signal. Revenue has grown from $5.2B in 2022 to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches like the EVOS PELVIC System highlight innovation, but the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show steady growth and a reasonable P/E of 18.95, weak sentiment and technical pressure near lows suggest limited near-term upside. Risks include execution challenges and competitive threats, but long-term investors may find value if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Genworth Financial Inc Common Stock
Genworth Financial, Inc. is a holding company that provides products and services related to aging and long-term care planning, and is the parent company of publicly traded mortgage insurer Enact Holdings, Inc.
Read more on GNW →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
